KED; Lys-Glu-Asp; Khavinson vascular bioregulator · Evidence-based safety and harm-reduction overview.
| Also known as | KED; Lys-Glu-Asp; Khavinson vascular bioregulator |
| Category | Peptide (research chemical) |
| Peptide sequence | Lys-Glu-Asp (KED); synthetic tripeptide |
| Developer | Saint Petersburg Institute of Bioregulation and Gerontology; Prof. Vladimir Khavinson |
| Regulatory status (US) | Not FDA-approved; research compound only; not for human consumption |
| Clinical trial registration | None - ClinicalTrials.gov returns zero results for Vesugen or KED |
| Human study sample sizes | Fewer than 100 subjects total across all published human observational reports |
| Independent Western replication | Essentially absent; evidence base is predominantly Khavinson-affiliated Russian publications |
| US legal status | Not FDA-approved for any indication. Sold in the United States exclusively as a research compound for laboratory use; not approved as a dietary supplement or pharmaceutical in the US or EU. Approved as a supplement in Russia and some Eastern European markets. Occupies a regulatory gray zone outside those jurisdictions. Not for human consumption under US law. |
Vesugen (KED; Lys-Glu-Asp) is a synthetic short-chain tripeptide bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson. It belongs to a family of Cytogen laboratory-synthesized peptides designed to mimic natural vascular tissue peptides and is hypothesized to support endothelial and vascular function through epigenetic modulation. It remains a preclinical and early observational research compound with no completed randomized controlled trials in any jurisdiction.
Vesugen is proposed to act via epigenetic regulation through interaction with gene promoter regions. Laboratory and animal studies suggest it may interact with promoters of MKI67/Ki-67 (cell division marker), SIRT1 (sirtuin-1 longevity pathway), and neuroplasticity-associated genes including GAP43 and SOD2. Reported downstream effects in preclinical models include enhanced mesenchymal stem cell proliferation, reduced cellular senescence markers, stimulation of nitric oxide production, and normalization of endothelial function. These proposed mechanisms have not been independently confirmed in Western laboratories, and the pathway-level evidence is largely derived from Khavinson-affiliated investigators.
Vesugen was developed at the Saint Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson (1946-2024), who directed the institute and published more than 775 papers on peptide bioregulators over his career. The tripeptide belongs to a broader class of Khavinson-designed short peptides intended to target specific tissue types. It has been available in Russia and some post-Soviet markets as a supplement and has attracted attention in English-language research peptide communities, but it has not been licensed to or developed by any pharmaceutical company outside Russia. Commercial availability in the West is exclusively through third-party research peptide vendors.
Evidence base is limited and of low methodological quality by Western regulatory standards. Animal data: In vivo rodent aging models and transgenic Alzheimer's (5xFAD) mice showed effects including dendritic spine density restoration at approximately 400 µg/kg IP dosing. In vitro: Cell-based studies in endothelial and vascular smooth muscle models provide some mechanistic corroboration. Human data: Only two to three small observational studies from Russian institutions have been published, with total combined sample sizes under 100 subjects. These studies were non-randomized, non-placebo-controlled, and lacked standardized adverse event reporting. No Phase I, II, or III clinical trials have been registered or completed in any jurisdiction - ClinicalTrials.gov returns no results for Vesugen or KED. Independent replication in Western peer-reviewed literature is essentially absent. The overall evidence base does not meet the standards required for regulatory approval in the US or EU.
Russian observational literature and preclinical work reference dosing parameters, but no dose-ranging studies have been performed in humans and no safe or effective human dose has been established. Animal studies used approximately 400 µg/kg IP in rodent models. Any dosing information circulating in research communities is informal and not supported by clinical trial data. This entry does not provide a dosing protocol. Consult a licensed clinician before considering any investigational peptide compound.
This is general research/context information, not medical advice or a recommended protocol.
No controlled stacking studies exist. Vesugen is sometimes grouped with other Khavinson-class vascular peptides (e.g., Cortagen, Cartalax) in Russian bioregulator protocols, but these combination uses have no clinical trial support and the interaction profiles are unknown. Any multi-peptide use compounds the absence of safety data.
NMN It To Win It. For the same cellular-aging/longevity goal, our NMN (a NAD+ precursor) is a legal supplement covering a similar mechanism.
See our recommended pickOrder your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.
Get tested with Ulta Lab Tests →No. Vesugen is not FDA-approved for any indication and is not recognized as a dietary supplement or pharmaceutical in the United States. It is sold legally only as a research compound for laboratory use.
The evidence base is limited and methodologically weak by Western regulatory standards. Human data consist of only two to three small, non-randomized, non-placebo-controlled Russian observational studies with fewer than 100 total subjects. No randomized controlled trials have been registered or completed in any jurisdiction. Animal and cell-based data provide mechanistic plausibility but are insufficient to establish efficacy or safety in humans.
No safe or effective human dose has been established through clinical trials. This reference does not provide dosing guidance. Anyone considering this or any investigational compound should consult a licensed clinician.
Preclinically only. One animal study in the transgenic 5xFAD mouse model of Alzheimer's disease reported restoration of dendritic spine density with IP dosing at approximately 400 µg/kg. No human Alzheimer's trials have been conducted or registered.
Formal Phase I safety data do not exist. Two signals from Russian studies warrant attention: prooxidant activity detected by chemiluminescence, and decreased CD34+ hematopoietic stem cells in one report, suggesting a possible bone marrow effect. No drug interaction studies have been done. The Russian literature reports general tolerability, but adverse event monitoring was not formally employed in those studies, so tolerability characterization is incomplete.
The original research was conducted at a Russian academic institute, not a pharmaceutical company. In Western markets, Vesugen is available only through third-party research peptide vendors not subject to FDA cGMP pharmaceutical manufacturing standards. Purity and identity should be independently verified via certificate of analysis before any laboratory use.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.